Clinical trials: Mastocytosis, Systemic
SSM, Mastocytosis, Indolent
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with…
- Conditions
- SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis
- Trial name
- NCT05186753
- Testing
- Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B)
- Where
- 57 sites in United States, Australia and 13 more
- Volunteers
- 237 people
- Sponsor
- Cogent Biosciences, Inc.
Systemic Mastocytosis
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
The goal of this clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied.
- Trial name
- NCT00449748
- Testing
- RAD001 (Everolimus)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Indolent Systemic Mastocytosis
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell…
- Trial name
- NCT04333108
- Testing
- Masitinib, Best Supportive Care
- Where
- 17 sites in France, Germany and 6 more
- Volunteers
- 140 people
- Sponsor
- AB Science
Aggressive Systemic Mastocytosis, Mast Cell Leukemia
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
This phase 2 trial studies ibrutinib to see how well it works in treating patients with systemic (affecting the entire body) mastocytosis that has spread to other parts of the body and usually cannot be cured or controlled with…
- Conditions
- Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis
- Trial name
- NCT02415608
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jason Robert Gotlib
Non Neoplastic Condition, Precancerous Condition
Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease. PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with relapsed or progressive…
- Trial name
- NCT00769587
- Testing
- thalidomide
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Systemic Mastocytosis
Use of Tamoxifen in Systemic Mastocytosis
In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to…
- Trial name
- NCT01334996
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic